Journal decision profile

New Biotechnology

Biochemistry, Genetics and Molecular Biology

New Biotechnology's 2026 Journal Metrics Score is 1.6, ranking Q3 in Biomedical Engineering and 1 other subfield. Two-year citation average from OpenAlex data, updated August 2026.

Elsevier BVNetherlandspISSN 1871-6784eISSN 1876-4347
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
1.6

Journal Metrics Score 2026 · 2021–2024 window citedness 6.40.

Review & acceptance time
i
Review & acceptance timeCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
138 daysmedian

Middle 50%: 101–217 days

99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025

New Biotechnology accepts papers a median of 138 days after submission, including peer review and revisions. That is slower than 73% of comparable journals with PubMed timing data.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$2,750

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit New Biotechnology?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
1.62026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#85 / 1,448LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
14.2%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.97MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
138 daysIQR 101–217 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
65 / yr2021–2024 AVG
Field-normalized top 10% share14.2%

37 of 260 works · same type, year & subfield

Field-normalized top 1% share1.5%

4 works · same type, year & subfield

Median FWCI0.97×

Below field-year expectation

Source output rank#85

of 1,448 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.97, so its typical recent paper runs about 3% below its field benchmark.

What does Top 10% Share mean?

14.2% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

9052016
992017
5632018
842019
822020
542021
622022
732023
712024
5552025

Recent work-type mix

260 OpenAlex works · 2021–2024

Article95.4%
Paratext3.1%
Erratum1.2%
Editorial0.4%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much New Biotechnology publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Algal biology and biofuel production20
Viral Infectious Diseases and Gene Expression in Insects19
biodegradable polymer synthesis and properties16
Microbial Metabolic Engineering and Bioproduction15
Monoclonal and Polyclonal Antibodies Research15
Biofuel production and bioconversion12
CRISPR and Genetic Engineering12
Enzyme Production and Characterization10
Diverse Scientific and Economic Studies8
SARS-CoV-2 and COVID-19 Research5
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 260 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Molecular BiologyQ4
Biomedical EngineeringQ3
BiotechnologyQ3

Is New Biotechnology a good journal?

A mid-ranked Q3 journal by citation data

By citation data, New Biotechnology is a mid-ranked journal: it is Q3 in Biomedical Engineering and 1 other subfield, the third quarter of journals by score, below the subfield median, and ranks #2,309 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 62%). New Biotechnology's 2026 Journal Metrics Score is 1.6. Recent papers took a median of 138 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $2,750 USD. OpenAlex classifies its papers in subfields including Molecular Biology, Biomedical Engineering, and Biotechnology, so check that your topic fits its scope.

Best quartile
Q3
Biomedical Engineering
Rank in Biology & Basic Science
#2,309 of 3,784
Top 62%
2026 Journal Metrics Score
1.6
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
138 days
Median, PubMed records
Open access fee (APC)
$2,750
OpenAlex, verify with the journal
Papers published in 2025
555
OpenAlex works

Check before you submit

  • Its output more than doubled, from 62 papers in 2022 to 555 in 2025. Fast-growing journals can change in scope and editorial standards, so read recent papers in your topic.
  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q3
Subfield Quartile
B2
CAS Block

Ranking and source check

#2,309
of 3,784 Biology & Basic Science field journals
#126
among Q3 Biology & Basic Science journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
5,778
H-Index
111
Fully Open Access
Yes
Recent OA Works
1,338
Subject Areas
Molecular BiologyBiomedical EngineeringBiotechnology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to New Biotechnology

  1. 1

    Check the scope

    OpenAlex classifies New Biotechnology's papers in subfields including Molecular Biology, Biomedical Engineering, and Biotechnology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    New Biotechnology homepage ↗
  3. 3

    Submit through Editorial Manager

    Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $2,750 USD for this open-access journal. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 138 days from submission to acceptance, including revisions (PubMed dates). New Biotechnology does not publish an acceptance rate.

Submission system from the publisher's author information, checked 2026-10-27. Individual journals can differ, so follow the link in the journal's own author guidelines.

Reviewer Two · coming soon

Know what reviewers will say before you submit to New Biotechnology

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about New Biotechnology

Is New Biotechnology a good journal?

By citation data, New Biotechnology is a mid-ranked journal: it is Q3 in Biomedical Engineering and 1 other subfield, the third quarter of journals by score, below the subfield median, and ranks #2,309 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 62%). New Biotechnology's 2026 Journal Metrics Score is 1.6. Recent papers took a median of 138 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $2,750 USD. OpenAlex classifies its papers in subfields including Molecular Biology, Biomedical Engineering, and Biotechnology, so check that your topic fits its scope.

What is New Biotechnology's Journal Metrics Score in 2026?

New Biotechnology's 2026 Journal Metrics Score is 1.6, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of New Biotechnology?

We have not found an official acceptance rate published by New Biotechnology or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 138 days from submission to acceptance. To judge selectivity, compare New Biotechnology's quartile and score with similar journals, or ask the editorial office.

What quartile is New Biotechnology in?

New Biotechnology's best quartile is Q3. By OpenAlex subfield: Q4 in Molecular Biology; Q3 in Biomedical Engineering; Q3 in Biotechnology. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for New Biotechnology will not match this score exactly. Compare journals using one source at a time.

How long does New Biotechnology take to accept a paper?

New Biotechnology accepts papers a median of 138 days after submission across 99 recent PubMed records with both dates; the middle half took 101–217 days. This includes peer review, editorial handling, and revisions.

How long is the peer review time at New Biotechnology?

PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at New Biotechnology, which includes peer review and revisions, has a median of 138 days. For the time to a first decision, check the journal's own website.

Is New Biotechnology faster than similar journals?

New Biotechnology's median of 138 days from submission to acceptance is slower than 73% of comparable journals with PubMed timing data.

How much does it cost to publish in New Biotechnology?

OpenAlex lists an indicative article processing charge of $2,750 USD for New Biotechnology. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to New Biotechnology?

Comparable journals include Biotechnology and Bioprocess Engineering, Biotechnology Advances, Critical Reviews in Biotechnology, and Biotechnology For Biofuels and Bioproducts. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to New Biotechnology?

Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 138 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search